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VASCULAR inflammation is thought to underlie the high morbidity and mortality of diseases such as acute lung 
injury, acute respiratory distress syndrome (ARDS), diabetes 
mellitus, and cancer.1–5 Therapeutic options are limited to 
the treatment of symptoms (e.g., lung-protective ventilation 
in patients with ARDS) rather than the cause of endothelial 
barrier dysfunction.6 Vascular hyperpermeability and endo-
thelial barrier dysfunction play key roles in the pathogenesis 
of vascular injury due to inflammation.6,7 The proinflamma-
tory cytokine tumor necrosis factor-α (TNFα) activates c-Src 
protein tyrosine kinase (Src) and increases endothelial per-
meability.8 Although the exact mechanism of TNFα-induced 
Src activation is not completely understood, it has been 
What We Already Know about This Topic
•	 The	 proinflammatory	 cytokine	 tumor	 necrosis	 factor-α	 acti-
vates	 Src	 tyrosine	 kinase	 and	 increases	 endothelial	 perme-
ability.	Whether	some	anti-inflammatory	effects	of	amide	local	
anesthetics	(such	as	those	observed	in	models	of	acute	lung	
injury)	 are	 due	 to	 inhibition	 of	 signaling	 upstream	 or	 down-
stream	of	Src	remains	unknown.
What This Study Tells Us That Is New
•	 Using	 human	 lung	 microvascular	 endothelial	 cells,	 it	 was	
shown	 that	 ropivacaine	 and	 lidocaine	 attenuated	 tumor	 ne-
crosis	 factor-α–induced	 neutrophil	 adhesion	 and	 endothelial	
hyperpermeability	via	a	reduction	of	Akt,	endothelial	nitric	ox-
ide	synthase,	and	Src	activation.
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ABSTRACT
Background: Pulmonary endothelial barrier dysfunction mediated in part by Src-kinase activation plays a crucial role in acute 
inflammatory disease. Proinflammatory cytokines, such as tumor necrosis factor-α (TNFα), activate Src via  phosphatidylinositide 
3-kinase/Akt-dependent nitric oxide generation, a process initiated by recruitment of  phosphatidylinositide 3-kinase regulatory sub-
unit p85 to TNF-receptor-1. Because amide-linked local anesthetics have  well-established anti-inflammatory effects, the authors 
hypothesized that ropivacaine and lidocaine attenuate inflammatory Src signaling by disrupting the phosphatidylinositide 
3-kinase–Akt–nitric oxide pathway, thus blocking Src-dependent neutrophil adhesion and endothelial hyperpermeability.
Methods: Human lung microvascular endothelial cells, incubated with TNFα in the absence or presence of clinically relevant concen-
trations of ropivacaine and lidocaine, were analyzed by Western blot, probing for phosphorylated/activated Src, endothelial nitric oxide 
synthase, Akt, intercellular adhesion molecule-1, and caveolin-1. The effect of ropivacaine on  TNFα-induced nitric oxide generation, 
co-immunoprecipitation of TNF-receptor-1 with p85, neutrophil adhesion, and endothelial barrier disruption were assessed.
Results: Ropivacaine and lidocaine attenuated TNFα-induced Src activation (half-maximal inhibitory concentration 
[IC50] = 8.611 × 10
−10 M for ropivacaine; IC50 = 5.864 × 10
−10 M for lidocaine) and endothelial nitric oxide synthase phos-
phorylation (IC50 = 7.572 × 10
−10 M for ropivacaine; IC50 = 6.377 × 10
−10 M for lidocaine). Akt activation (n = 7; P = 0.006) 
and  stimulus-dependent binding of TNF-receptor-1 and p85 (n = 6; P = 0.043) were blocked by 1 nM of ropivacaine. 
 TNFα-induced neutrophil adhesion and disruption of endothelial monolayers via Src-dependent intercellular adhesion 
 molecule-1- and caveolin-1-phosphorylation, respectively, were also attenuated.
Conclusions: Ropivacaine and lidocaine effectively blocked inflammatory TNFα signaling in endothelial cells by attenuating 
p85 recruitment to TNF-receptor-1. The resultant decrease in Akt, endothelial nitric oxide synthase, and Src phosphorylation 
reduced neutrophil adhesion and endothelial hyperpermeability. This novel anti-inflammatory “side-effect” of ropivacaine and 
lidocaine may provide therapeutic benefit in acute inflammatory disease. (Anesthesiology 2014; 120:1414-28)
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demonstrated that endothelial nitric oxide synthase (eNOS)–
mediated nitric oxide production downstream of phosphati-
dylinositide 3-kinase (PI3K)-dependent activation of Akt9–11 
and CaM kinase II induce Src activation.10,12 TNFα-induced 
PI3K activation is thought to be initiated by recruitment of 
PI3K regulatory subunit p85 to TNF-receptor-1 (TNF-R1) 
upon agonist binding.13 Downstream signaling of activated 
Src includes phosphorylation of intercellular adhesion mol-
ecule-1 (ICAM-1) and caveolin-1, which have both been 
shown to contribute to the development of the endothelial 
injury and inflammatory hyperpermeability.14–17
Experimental evidence indicates that amide-linked local 
anesthetics such as ropivacaine and lidocaine exhibit beneficial 
properties during the pathogenesis of acute lung injury: they 
were proven to attenuate experimental  (endotoxin-induced) 
lung inflammation in vivo and in vitro18,19 as well as 
neutrophil-dependent acute lung injury induced by 
 N-formyl-L-leucine-methionyl-L-phenylalanine20,21 In addi-
tion, we recently demonstrated inhibition of TNFα-induced 
Src activation by ropivacaine and lidocaine in a human lung 
cancer cell line in vitro.22 We therefore hypothesized that 
amide-linked local anesthetics, such as ropivacaine and lido-
caine, may attenuate inflammatory Src signaling and subse-
quent ICAM-1 and caveolin-1 phosphorylation by disrupting 
the PI3K–Akt–nitric oxide signaling pathway, thus blocking 
Src-dependent vascular inflammation and hyperpermeability 
of the endothelium. The results of the current study indicate 
a novel anti-inflammatory mechanism by which ropivacaine 
and lidocaine may minimize endothelial injury during the 
pathogenesis of acute lung injury or ARDS.
Materials and Methods
Cell Culture
Human lung microvascular endothelial cells (HLMVECs; 
Lonza, Walkersville, MD) were cultured on dishes coated 
with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO) in Vas-
cuLife® Basal Medium (Lifeline Cell Technology, Walkers-
ville, MD) supplemented with the VascuLife® VEGF-Mv 
LifeFactors Kit containing 5% fetal bovine serum, 10 mM 
of  L-glutamine, 5 ng/ml of recombinant vascular endothe-
lial growth factor, 5 ng/ml of recombinant epithelial growth 
factor, 5 ng/ml of fibroblast growth factor, 15 ng/ml of 
insuline-like growth factor-1, 1 μg/ml of hydrocortisone 
hemisuccinate, 0.75 U/ml of heparin, 50 μg/ml of ascorbic 
acid (Lifeline Cell Technology), and 1% penicillin–strepto-
mycin (Gibco Invitrogen, Carlsbad, CA). Experiments were 
performed with 70 to 100% confluent cells from passages 5 
to 11. Before the experiments, cells were grown in a serum-
free media (VascuLife® Basal Medium) for 16 h. All cells 
were maintained in 5% carbon dioxide–95% room air in a 
water-jacketed 37°C incubator.
Experimental Procedures
Cell monolayers were incubated with TNFα (Gibco Invit-
rogen) at a concentration of 20 ng/ml diluted in VascuLife® 
Basal Medium for 20 min for Western blot analysis or for 
10 min for immunoprecipitation. Ropivacaine 0.5% (Naro-
pin®; APP Pharmaceuticals, Schaumburg, IL) or lidocaine 
2% (APP Pharmaceuticals) were diluted with VascuLife® 
Basal Medium (1 pM to 100 μM) and were incubated for 
the same time period as TNFα. If tested together on the 
same cell monolayer, ropivacaine and TNFα were added to 
the medium simultaneously.
Cell Harvest and Lysis
After the indicated incubation times, HLMVECs were 
washed once with ice-cold phosphate-buffered saline (Gibco 
Invitrogen), scraped from the bottom of the plate, collected, 
and lysed with radio-immunoprecipitation buffer (Boston 
Bioproducts, Ashland, MA) supplemented with protease 
inhibitor cocktail, 200 mM of phenylmethylsulfonyl fluo-
ride, 1 mM of EDTA, 1 mM of sodium fluoride, and 1 mM 
of sodium orthovanadate (all from Sigma-Aldrich) as previ-
ously described.22,23
Determination of Total Protein Concentration
Whole cell lysates prepared as described above were subject 
to total protein concentration measurement using the DC 
Protein Assay Kit (BioRad, Hercules, CA) in accordance 
with the manufacturer’s instructions. Immunoglobulin G 
was used for the generation of a standard curve.
Immunoprecipitation
To assess the association of TNF-R1 and p85 subunit 
of PI3K, HLMVECs were washed once with ice-cold 
 phosphate-buffered saline (Gibco Invitrogen) and lysed 
using a buffer consisting of 20 mM of Tris-HCl (pH 7.4), 
150 mM of NaCl, 1.2% Triton X-100, protease inhibitor 
cocktail, 200 mM of phenylmethylsulfonyl fluoride, 1 mM 
of EDTA, 1 mM of sodium fluoride, and 1 mM of sodium 
orthovanadate for 20 min during gentle rocking of the dish 
at 4°C as previously described.13 Lysates were then incubated 
with magnetic sheep anti-mouse-IgG–coated Dynabeads 
(Gibco Invitrogen) for 1 h at 4°C that had previously been 
incubated for 30 min at 4°C with nonspecific mouse immu-
noglobulin G (the negative control) or anti-TNF-R1 mono-
clonal antibody (both from Santa Cruz Biotechnology). The 
lysate-bead suspensions were then placed in a magnetic par-
ticle concentrator (Invitrogen, Carlsbad, CA) and the pellet 
washed thrice with ice-cold (4°C) Ca2+- and Mg2+-free phos-
phate-buffered saline (Gibco Invitrogen) that also included 
the same supplements as the lysis buffer (see Materials and 
Methods, Cell harvest and lysis). Laemmli sample buffer (×2; 
BioRad) was added together with dithiothreitol (final con-
centration of 30 mM; Sigma-Aldrich). The suspension was 
then boiled for 5 min to elute the protein complexes from 
the beads. After removal of the beads by magnetic separa-
tion, samples were directly loaded on a 10% sodium dodecyl 
sulfate-polyacrylamide gel for electrophoresis and Western 
blot analysis or stored at −80°C until further use.
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Western Blot Analysis
Western blotting of whole cell lysates was carried out as pre-
viously described.22,23 Antibodies against pY419 Src, total 
Src, and p85 were purchased from Cell Signaling Technolo-
gies (Danvers, MA), for pY512 ICAM-1, total ICAM-1, 
glyceraldehyde 3-phosphate dehydrogenase, and TNF-R1 
(both rabbit and mouse origin) from Santa Cruz Biotechnol-
ogy, and for pY14 caveolin-1, total caveolin-1, and β-actin 
from BD Biosciences (Franklin Lakes, NJ).
In Vitro Src Kinase Assay
Src kinase activity in the absence or presence of different 
concentrations of ropivacaine (1 nM to 1 mM) or the Src 
inhibitor  4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)
pyrazolo[3,4-d]pyrimidine (PP2, 10 μM; from Calbiochem 
Millipore, Billerica, MA) was assessed using an assay previ-
ously described by Hastie et al.,24 which uses the incorpora-
tion of radioactively labeled [γ-32P]-adenosine triphosphate 
(Perkin Elmer, Waltham, MA) into a specific substrate pep-
tide. Both purified, active Src and its specific substrate pep-
tide were purchased from Millipore. Radioactivity, expressed 
as counts per minute (cpm), was measured in a γ-scintillation 
counter (Beckman Coulter, Indianapolis, IN).
PI3K In Vitro Kinase Assay
Assessment of PI3K activity in vitro was carried out with a 
commercially available PI3K activity/inhibitor assay kit (Mil-
lipore) according to the manufacturer’s instructions. The 
assay is based on the principle of an enzyme-linked immu-
nosorbent assay and detects biotinylated phosphatidylinositol 
(3,4,5)-triphosphate (B-PIP3) captured with general receptor 
for phosphoinositides-1 bound to plates coated with glutathi-
one using a streptavidin-horse radish peroxidase conjugate and 
colorimetric readout at 450 nm. PI3K converts  biotinylated 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to PIP3. The 
generated PIP3 competes with added B-PIP3 for glutathi-
one binding. A high signal in the colorimetric readout there-
fore indicates low levels of generated PIP3, thus low enzyme 
activity. We evaluated different concentrations of ropivacaine 
(Sigma-Aldrich; solved in dimethyl sulfoxide, final concentra-
tion of 1 nM, 1 μM, or 100 μM), as potential PI3K inhibitors 
and used wortmannin (100 nM), a known PI3K inhibitor, as a 
positive control. Four different isoforms of the p110 catalytic 
subunit of PI3K (α, β, γ, δ) were tested separately.
Measurement of Nitrite Ion Accumulation and Nitric Oxide 
Production in HLMVEC
Chemiluminescence measurement of nitrite ion accumulation in 
cell culture supernatant, which is directly proportional to nitric 
oxide production, was conducted with a Sievers® NOA 280i high-
performance liquid chromatography with fluorescence detec-
tion (General Electric, Boulder, CO) as previously described.11 
HLMVEC monolayers were treated with TNFα (20 ng/ml) in 
the absence or presence of different concentrations of ropivacaine 
(1 nM, 1 μM, or 100 μM). For some experiments, the cells were 
pretreated with the NOS inhibitor N5-(1-iminoethyl)-L-orni-
thine dihydrochloride (L-NIO; Cayman Chemical, Ann Arbor, 
MI) for 1 h before the application of TNFα.
Transendothelial Resistance
Human lung microvascular endothelial cells were grown 
to confluence on goldfilm electrodes (ECIS cultureware; 
Applied Biophysics, Troy, NY) coated with 0.2% gelatin. 
Electrical impedance across the monolayer was measured at 
1 V, 4,000 Hz with the Electric Cell-Substrate Impedance 
Sensing system (Applied Biophysics) over time as previously 
described.25 After an equilibration time of 30 min, TNFα 
was added with or without ropivacaine at a final concentra-
tion of 1 μM. For some experiments, cells were treated with 
the NOS inhibitor L-NIO (Cayman Chemical) before the 
addition of TNFα. Impedance values were used to calculate 
resistance using ECIS software.
Isolation of Human Polymorphonuclear Leukocytes
Whole blood samples were drawn from cubital veins from 
healthy donors and anticoagulated with 1 ml acid–citrate–
dextrose (Sigma-Aldrich) per 5 ml whole blood according to 
approved Institutional Review Board (University of Illinois 
at Chicago, Chicago, IL) protocol. Samples were suspended 
in a three-fold volume of ice-cold lysis medium contain-
ing 155 mM of ammonium chloride and 10 mM of potas-
sium bicarbonate (both from Sigma-Aldrich) and kept on 
ice for 10 min. After brief centrifugation at 1,500 rpm and 
4°C (Eppendorf Centrifuge 5804 R; Eppendorf, Hamburg, 
Germany), the supernatant was discarded and the cell pellet 
was resuspended in 2 ml of ice-cold lysis medium supple-
mented with 0.5% bovine serum albumin. The suspension 
was then kept on ice 15 min followed by another centrifu-
gation at 1,500 rpm and 4°C. Again, the supernatant was 
discarded. The pellet was resuspended in 2 ml of ice-cold 
Dulbecco phosphate-buffered saline (Gibco Invitrogen) and 
layered on 2 ml of Ficoll Histopaque 1077 (Sigma-Aldrich). 
After 30 min of centrifugation at 1,500 rpm and 4°C with 
low brake, the supernatant was discarded and the pellet con-
sisting of neutrophils was resuspended in Hank balanced salt 
solution (Gibco Invitrogen). Viability was 95% or more as 
assessed with Trypan blue staining (Sigma-Aldrich).
Neutrophil Adhesion Assay
Neutrophil adhesion to a monolayer of HLMVECs was 
assessed by using the CytoSelect® Leukocyte-Endothelium 
Adhesion Assay (Cell Biolabs, San Diego, CA) in accordance 
with the manufacturer’s instructions.17 In brief, HLMVECs 
were grown in a 96-well plate (BD Biosciences) coated with 
0.2% gelatin (Sigma-Aldrich). To increase ICAM-1 expres-
sion, all cells were subject to stimulation with Escherichia coli 
serotype 055:B5 lipopolysaccharide (Sigma-Aldrich) at a con-
centration of 4 μg/ml for 4 h. Cells were then stimulated with 
TNFα in the absence or presence of ropivacaine at different 
concentrations (1 nM, 1 μM, or 100 μM) for 20 min before 
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addition of fluorescently labeled, freshly isolated human 
neutrophils (100,000 per well). After an incubation period 
of 30 min, nonadherent neutrophils were washed away and 
remaining cells were lysed; fluorescence of the lysate was mea-
sured at 485/535 nm (excitation/emission).
Determination of Half-maximal Inhibitory Concentration 
(IC50) and Maximum Effect Size
The half-maximal inhibitory concentration (IC50) is defined as 
the concentration of a drug where it exerts 50% of its maximum 
effect.26 To determine these values for the effect of ropivacaine 
and lidocaine on TNFα-induced Src and eNOS activation, 
densitometry data obtained from Western blot experiments 
(mean ± SD, normalized to values of TNFα alone, set as 1.0) 
were plotted against the (logarithmic) concentration of the 
local anesthetic used in the experiment. A concentration–
response curve with a Hill slope of −1.0 was fitted by nonlinear 
regression analysis using the following equation:
Y X IC= + − + −Bottom Top Bottom( ) / ( )( Log )1 10 50
Results are reported as values with 95% CI (for IC50, top, 
and bottom). Nonlinear regression curve fitting was com-
puted with GraphPad Prism software for Mac, Version 6 
(GraphPad Software, La Jolla, CA).
Statistical Analysis
For Western blot, Src and PI3K activity assay, and transen-
dothelial resistance (TER) data, normal distribution was 
assessed using a Shapiro–Wilk test. Normally distributed 
data were analyzed by one-way ANOVA with Bonferroni 
post hoc testing to correct for multiple testing and to keep the 
family-wise error rate less than 0.05. Not-normally distrib-
uted data were analyzed with nonparametric testing methods 
(Kruskal–Wallis tests) with Dunn post hoc correction.
Nitric oxide production and fluorescence from adhesion 
experiments were analyzed by using a two-way ANOVA with 
the local anesthetic and the absence or presence of TNFα as 
factors to be tested. Bonferroni post hoc testing was then used to 
detect significant differences between the different concentra-
tions of ropivacaine in the absence or presence of TNFα (one 
family for all comparisons). Experimental data are presented 
as mean ± SD. All tests were performed two-sided and non-
blinded using GraphPad Prism software for Mac, Version 6 
(GraphPad Software). A P value of less than 0.05 was consid-
ered to be statistically significant. A few single values (approxi-
mately 5 to 7) were lost to observation due to unfortunate and 
unexpected technical difficulties during the experiment.
Results
Ropivacaine and Lidocaine Inhibit the Activation of Src 
Tyrosine Kinase (Src) in HLMVEC but Do Not Act as Direct, 
Adenosine Triphosphate-competitive Src Inhibitors
We first assessed the effect of ropivacaine and lidocaine at a con-
centration of 1 nM on TNFα (20 ng/ml for 20  min)-induced 
activation of Src in HLMVEC. Western blot analysis of active-
site Src phosphorylation  (phospho-tyrosine 419; pY419 Src) 
and total Src protein level in whole cell lysates (fig. 1A) indi-
cated that TNFα treatment of cells increased Src activity 2.3-
fold compared with untreated cells (2.3 ± 0.93 [mean ± SD], 
P = 0.006, fig. 1Bi, and 2.3 ± 0.51, P = 0.004, fig. 1Bii). The 
TNFα-induced response was then reduced by 50 ± 9% in 
presence of 1 nM of ropivacaine (P = 0.035; fig. 1Bi) and by 
49 ± 16% by lidocaine (1 nM; P = 0.034), which in both cases 
brought the level of Src activation nearly to baseline values. 
Neither ropivacaine nor lidocaine, even at concentrations of 
100 μM, altered Src phosphorylation significantly compared 
with untreated cells (Kruskal–Wallis test; P = 0.534 for ropi-
vacaine; P = 0.946 for lidocaine, data not shown).
To determine the IC50 of the observed inhibition of 
TNFα-induced Src activation by ropivacaine and lidocaine, 
another series of Western blot analyses treating HLMVEC 
with TNFα in the absence or presence of a broad range of 
concentrations of both ropivacaine and lidocaine (1 pM to 
1 μM) was conducted. Figure 1C shows the ratio of pY419 
Src over total Src (mean ± SD) plotted against the logarith-
mic concentration of either ropivacaine (fig. 1Ci) or lido-
caine (fig. 1Cii) relative to TNFα alone. We then analyzed 
the data using nonlinear regression curve fitting. The results 
are summarized in table 1. The IC50 for TNFα-induced Src 
activation was 861 pM (95% CI, 79 pM to 9.4 nM) for ropi-
vacaine and 586 pM (59.6 pM to 6.8 nM) for lidocaine. The 
maximum observed effect was 56% (95% CI, 68.9 to 43) for 
ropivacaine and 39% (55.8 to 23.3) for lidocaine.
To clarify whether ropivacaine blocks TNFα-induced Src 
activation as opposed to functioning as a competitive  active-site 
Src inhibitor, we performed an in vitro Src kinase assay using 
radiolabeled [γ-32P] adenosine triphosphate (fig. 1D). Purified 
active Src kinase (15 ng) was incubated with a Src-specific sub-
strate peptide (250 μM) in the absence or presence of either 
the Src inhibitor PP2 (10 μM) or different concentrations 
of ropivacaine (1 nM to 1 mM). Only the Src inhibitor PP2 
reduced Src activity in this setting (P = 0.0008); ropivacaine 
did not alter Src activity at any of the concentrations tested 
(P = 1 for all groups compared with positive control substrate 
+ enzyme, fig. 1D), and thus is not a direct inhibitor of c-Src.
Ropivacaine (and Lidocaine) Block TNFα-induced eNOS 
Phosphorylation and Nitric Oxide Production in HLMVECs
The generation of nitric oxide can promote Src activation in 
response to different stimuli.10 We therefore assessed eNOS 
activation by Western blot analyses of active-site serine 1177 
phosphorylation in HLMVEC lysates treated with TNFα in 
the absence or presence of 1 nM of ropivacaine or lidocaine. 
As shown in figure 2, A and B, TNFα treatment induced a 
2.76 ± 1.39-fold (P = 0.002) increase in eNOS phosphoryla-
tion (pS1177 eNOS) and this response to TNFα was reduced 
by 45 ± 15% in presence of 1 nM of ropivacaine (P = 0.022; 
fig. 2, Ai and Bi). Lidocaine at 1 nM concentration significantly 
reduced TNFα-induced eNOS phosphorylation (2.68 ± 0.66; 
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Fig. 1. Ropivacaine and lidocaine inhibit the activation of Src tyrosine kinase (Src) in human lung microvascular endothelial cells 
(HLMVECs). (A) Representative Western blots of Src phosphorylated at tyrosine 419 (pY419 Src, row 1), total Src (row 2), and 
β-actin (row 3) after treatment with tumor necrosis factor-α (TNFα) in the absence or presence of (i) ropivacaine (1 nM) or (ii) 
lidocaine for 20 min. (B) Quantitative analysis of densitometry of Western blots showing the ratio of pY419 Src over total Src in 
HLMVEC treated with TNFα (20 ng/ml) in the absence (black bar) or presence (striped gray bar) of (i) ropivacaine or (ii) lidocaine 
compared with untreated cells (white bar, set as 1.0). Data shown are mean ± SD (n = 6 per group); #P < 0.05 versus untreated 
cells, *P < 0.05 compared with TNFα alone. (C) Dose–response curve of Western blot densitometry data showing the ratio of 
pY419 Src over total Src in HLMVEC treated with TNFα (20 ng/ml) in the absence or presence of (i) ropivacaine (1 pM to 1 μM) or 
(ii) lidocaine (1 pM to 1 μM) compared with TNFα alone (set as 1.0). Data shown are mean ± SD (n = 5–6). (D) In vitro Src kinase 
activity. Purified, active Src kinase (15 ng) was incubated with radiolabeled [γ-32P] adenosine triphosphate, a specific substrate 
peptide (250 μM) in the absence (black bar) or presence of either the Src inhibitor PP2 (10 μM, striped gray bar) or different 
concentrations of ropivacaine (1 nM to 1 mM, gray bars). Data shown are mean ± SD of radioactive counts per minute (cpm) as a 
measure of [γ-32P] adenosine triphosphate turnover and therefore Src enzyme activity (n = 3 per group); #P < 0.05 versus enzyme 
or substrate alone, *P < 0.05 compared with enzyme plus substrate. GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
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P = 0.011; fig. 2, Aii and Bi) by 49 ± 32% (P = 0.022; fig. 2, 
Aii and Bii). The dose–response relationship for inhibition of 
TNFα-induced eNOS phosphorylation by both ropivacaine 
and lidocaine (fig. 2C) revealed an IC50 of 757 pM (95% CI, 
117.7 pM to 4.9 nM; table 1) for ropivacaine, which had a 
maximal effect of 39.4% (58.9 to 19.8), whereas lidocaine 
showed an IC50 of 638 pM (92 pM to 44.2 nM) and a maxi-
mum effect of 54% (74.4 to 35.4; table 1) in these experiments. 
Neither ropivacaine nor lidocaine, even at concentrations of 
100 μM, directly altered eNOS phosphorylation compared 
with untreated cells (Kruskal–Wallis test, P = 0.972 for ropi-
vacaine; P = 0.359 for lidocaine, data not shown).
The effect of ropivacaine at different concentrations 
(1 nM, 1 μM, and 100 μM) on TNFα-induced (20 ng/ml) 
nitric oxide production in HLMVEC as compared with cells 
treated with the NOS-inhibitor L-NIO (20 μM) was exam-
ined. Data analysis using two-way ANOVA with the presence 
of TNFα and the different experimental treatments (L-NIO 
or ropivacaine) as the factors to be tested revealed a signifi-
cant impact of the presence of TNFα (F(1, 31) = 40.35; 
P < 0.0001) and the different drugs and doses on nitric 
oxide production by the cells (F(4, 31) = 25.93; P < 0.0001). 
A significant interaction term between the two factors 
(F(4, 31) = 16.55; P < 0.0001) was also found. Post hoc testing 
revealed significant differences between L-NIO and the differ-
ent concentrations of ropivacaine when incubated together 
with TNFα compared with TNFα alone (P < 0.0001 for all 
comparisons). As shown in figure 2D, the TNFα-induced 
increase was completely abolished by pretreating the cells 
with L-NIO and 1 nM of ropivacaine. However, the presence 
of neither ropivacaine nor L-NIO had an effect on basal nitric 
oxide production (P = 1 for all comparisons; fig. 2D).
Ropivacaine Blocks TNFα-induced Activation of Akt 
Upstream of eNOS but Does Not Directly Inhibit PI3K 
Activity Upstream of Akt
To establish the mechanism by which ropivacaine blocks 
TNFα-induced eNOS and Src activation, we determined 
whether ropivacaine blocks TNFα-induced activation of 
Akt, an upstream kinase known to activate eNOS11 via 
phosphorylation of serine 1177. HLMVECs exposed to rop-
ivacaine (1 nM, 1 μM) in the absence or presence of TNFα 
(20 ng/ml) for 20 min were subject to Western blot analysis, 
probing for “activated” Akt, phosphorylated at threonine 
308 (pT308 Akt, the PI3K-dependent phosphorylation 
site),27 as well as total Akt which served as a loading con-
trol (fig. 3A). Densitometry analysis revealed that ropi-
vacaine alone had no effect on basal Akt phosphorylation 
(P = 0.878, data not shown), whereas the TNFα-induced 
increase in Akt phosphorylation (214 ± 44% of untreated 
cells; P = 0.013) was completely abolished by 1 nM of ropi-
vacaine (P = 0.005; fig. 3B). As Akt activation is known to 
be induced by PI3K,11,28 we determined whether ropiva-
caine might act as a direct inhibitor of PI3K catalytic activ-
ity. PI3K activity in vitro was determined by enzyme-linked 
immunosorbent assay measurements of PIP3 generated by 
PI3K. In this particular assay, a high signal indicates poor 
competition with B-PIP3 and low enzyme activity. Different 
isoforms of p110 (α, β, γ, and δ), the catalytic subunit of 
PI3K, were incubated with PIP2 substrate in the absence or 
presence of different concentrations of either ropivacaine or 
wortmannin (100 nM), a known PI3K inhibitor.17 As shown 
in figure 3C, wortmannin decreased p110 activity, whereas 
ropivacaine had no significant effect on the activity of the 
four PI3K isoforms tested (fig. 3C).
To determine whether ropivacaine blocks Akt-dependent 
eNOS activation (and thereby prevents Src activation) spe-
cifically, Ca2+-dependent eNOS activation in the presence or 
absence of ropivacaine was assessed. HLMVECs were stimu-
lated with the Ca2+ ionophore A23187 (5 μM) for 10 min to 
activate eNOS via Ca2+/calmodulin10 and subsequently Src 
via nitric oxide signaling rather than Akt signaling10 (fig. 4). 
A23187 treatment induced a 45 ± 34.8% increase in Src 
activity compared with control (P = 0.079; fig. 4, A and B); 
however, this effect was not blocked by 1 μM of ropivacaine 
(P = 1; fig. 4, A and B).
Ropivacaine Blocks Recruitment of p85 Regulatory 
Subunit of PI3K to TNF-R1
The recruitment of p85 regulatory subunit of PI3K to 
 TNF-R1 is a key step leading to PI3K activation on binding 
of TNFα to TNF-R1.13 To detect the recruitment of p85, 
TNF-R1 was immunoprecipitated from HLMVEC lysates 
which were briefly (10 min) stimulated with TNFα in the 
absence or presence of ropivacaine at 1 nM. Western blots 
of the immunoprecipitated protein (fig. 5A) showed a sta-
tistically significant 4.46 ± 1.92-fold increase (P = 0.002) in 
co-immunoprecipitation of p85 and TNF-R1 compared with 
untreated cells (fig. 5B) which was attenuated by 64 ± 14.6% 
in presence of 1 nM ropivacaine (P = 0.04; fig. 5B).
Table 1. Inhibitory Properties of Ropivacaine and Lidocaine on TNFα-induced Src and eNOS Phosphorylation
Drug Enzyme IC50 (M) (95% CI) Bottom (95% CI) Top (95% CI)
Ropivacaine pY419 Src 8.611 × 10−10 (7.901 × 10−11 to 9.384 × 10−9) 0.441 (0.311–0.570) 0.870 (0.719–1.022)
pS1177 eNOS 7.572 × 10−10 (1.177 × 10−10 to 4.872 × 10–9) 0.606 (0.411–0.802) 1.268 (1.08–1.456)
Lidocaine pY419 Src 5.864 × 10−10 (5.964 × 10−11 to 5.765 × 10−9) 0.614 (0.462–0.767) 1.111 (0.942–1.279)
pS1177 eNOS 6.377 × 10−10 (9.200 × 10−11 to 4.420 × 10−8) 0.456 (0.266–0.646) 1.198 (0.975–1.420)
IC50  =  half-maximal inhibitory concentration; pS1177 eNOS  =  endothelial nitric oxide synthase, phosphorylated at serine 1177 (active eNOS); pY419 
Src = Src, phosphorylated at tyrosine 419 (active Src).
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Fig. 2. Ropivacaine and lidocaine inhibit endothelial nitric oxide synthase (eNOS) phosphorylation and ropivacaine blocks tu-
mor necrosis factor-α (TNFα)–induced nitric oxide (NO) production in human lung microvascular endothelial cells (HLMVEC). 
(A) Representative Western blots of eNOS phosphorylated at serine 1177 (pS1177 eNOS, row 1), total eNOS (row 2), and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH, row 3) after treatment with TNFα (20 ng/ml) in the absence or presence of (i) 
ropivacaine (1 nM) or (ii) lidocaine (1 nM) for 20 min. (B) Quantitative analysis of densitometry of Western blots showing the ratio 
of pS1177 eNOS over total eNOS in HLMVEC treated with TNFα (20 ng/ml) in the absence or presence of (i) ropivacaine (1 nM) 
or (ii) lidocaine (1 nM) compared with untreated cells (set as 1.0). Data shown are mean ± SD (n = 6); #P < 0.05 versus untreated 
cells, *P < 0.05 compared with TNFα alone. (C) Dose–response curve of Western blot densitometry data showing the ratio of 
pS1177 eNOS over total eNOS in HLMVEC treated with TNFα (20 ng/ml) in the absence or presence of log concentrations of (i) 
ropivacaine (1 pM to 1 μM) or (ii) lidocaine (1 pM to 1 μM) compared with TNFα alone (set as 1.0). Data shown are mean ± SD 
(n = 6–8 for ropivacaine and n = 5–6 for lidocaine). (D) Assessment of cumulative NO production via chemiluminescent detection 
of nitrite ion (NO2
–) directly proportional to NO in HLMVEC culture supernatants after treatment for 1 h with ropivacaine (1 nM, 
1 μM, 100 μM) or the nonselective NO-synthase inhibitor N5-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) (20 μM) in the 
absence (empty circles) or presence (black squares) of TNFα (20 ng/ml). NO production from untreated cells was set as 1.0. Data 
shown are mean ± SD; n = 3 per group, except for TNFα alone and data with L-NIO, where n = 6. #P < 0.05 versus untreated 
cells, *P < 0.05 compared with TNFα alone.
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Ropivacaine Inhibits Src-dependent Phosphorylation of 
ICAM-1 and Neutrophil Adhesion to Endothelial Cells
Src-dependent phosphorylation of ICAM-1 is known 
to increase leukocyte adhesion in endothelial cells.16 
We therefore first assessed whether ropivacaine inhibits 
 TNFα-induced ICAM-1 phosphorylation in our cell cul-
ture model. HLMVEC lysates, incubated with different 
concentrations of ropivacaine (1 nM, 1 μM) in the absence 
or presence of TNFα, were analyzed via Western blot, prob-
ing for phosphorylated ICAM-1 (at tyrosine 512, pY512 
ICAM-1), and total ICAM-1 (fig. 6A). Densitometry anal-
ysis revealed that there was no alteration in basal pY512 
ICAM-1 level in presence of ropivacaine alone (P = 0.537, 
data not shown). However, when applied in combination 
with TNFα, ICAM-1 phosphorylation observed in response 
to TNFα alone (175 ± 94.2% compared with untreated cells; 
P = 0.007) was reduced by 45 ± 23% in presence of 1 nM 
ropivacaine (P = 0.107) and was completely blocked by 1 
μM (P = 0.006; fig. 6B). To assess the functional significance 
of the observed inhibition of ICAM-1 phosphorylation, 
Fig. 3. Ropivacaine blocks activation of Akt kinase (Akt) up-
stream of endothelial nitric oxide synthase (eNOS) but does not 
directly inhibit phosphatidylinositide 3-kinase (PI3K) upstream of 
Akt. (A) Representative Western blot of Akt phosphorylated at 
threonine 308 (pT308 Akt, row 1), total Akt (row 2), and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH, row 3) after 
treatment with tumor necrosis factor α (TNFα, 20 ng/ml) in the 
absence or presence of ropivacaine (1 nM, 1 μM) for 20 min. 
(B) Quantitative analysis of densitometry of Western blots showing 
the ratio of pT308 Akt over total Akt in human lung microvascu-
lar endothelial cells treated with TNFα (20 ng/ml) in the absence 
(black bar) or presence (striped gray bars) of ropivacaine (1 nM, 
1 μM) compared with untreated cells (set as 1.0). Data shown 
are mean ± SD (n = 7 per group); #P < 0.05 versus untreated 
cells, *P < 0.05 compared with TNF-α alone. (C) PI3K activity 
measured by enzyme-linked immunosorbent assay of biotinyl-
ated phosphatidylinositol (3,4,5)-triphosphate (B-PIP3) after in-
cubation of different isoforms of p110 catalytic subunit of  PI3K 
(α, β, γ, δ) with phosphatidylinositol (4,5)-bisphosphate (PIP2) 
substrate and ropivacaine (1 nM, 1 μM, 100 μM) or wortman-
nin (100 nM). Generated PIP3 competes with added B-PIP3 for 
binding, thus a high signal indicates low enzyme activity. Data 
shown are mean ± SD (n = 4 per group); #P < 0.05 versus all 
other groups.
Fig. 4. Ropivacaine does not block Src activation induced by 
the non-Akt–dependent endothelial nitric oxide synthase ac-
tivator calcium ionophore (A23187). (A) Representative West-
ern blot of pY419 Src (row 1), total Src (row 2), and β-actin 
(row 3) after treatment with the non-Akt–dependent endothe-
lial nitric oxide synthase activator calcium ionophore (A23187, 
5 μM) in the absence or presence of ropivacaine (1 nM, 1 μM) 
for 10 min. (B) Quantitative analysis of densitometry of West-
ern blots showing the ratio of pY419 Src over total Src after 
stimulation with A23187 alone (black squares), A23187 with 
ropivacaine (1 nM, 1 μM, gray squares), or vehicle-treated 
cells (empty circles, set as 1.0) for 10 min. Data shown are 
mean ± SD (n = 4); #P < 0.05 versus vehicle.
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we quantified neutrophil adhesion to HLMVEC mono-
layers. Before the addition of TNFα (20 ng/ml) ± ropiva-
caine (1 nM, 1 μM, 100 μM) for 20 min, HLMVECs were 
stimulated with lipopolysaccharide (4 μg/ml) for 4 h to 
increase ICAM-1 expression as shown in the Western blot 
in figure 6Ci. Quantification of adherent, fluorescently 
labeled human neutrophils revealed a 63 ± 27.6% increase 
in adhesion in cells treated with TNFα for 20 min. Anal-
ysis with two-way ANOVA revealed a significant effect of 
both TNFα (F(1, 56) = 14.14; P < 0.001) and ropivacaine 
(F(3, 56) = 6.765; P < 0.001) and a significant interac-
tion term between these two factors (F(3, 56) = 5.177; P 
< 0.001). Post hoc comparison between the values obtained 
from incubation with TNFα alone and ropivacaine at dif-
ferent concentrations incubated together with TNFα 
revealed a dose-dependent inhibition of neutrophil adhe-
sion by increasing ropivacaine concentrations (statistically 
significant decrease at a concentration of 1 nM ropivacaine 
[P = 0.01] and higher; fig. 6Cii).
Fig. 5. Ropivacaine blocks recruitment of p85 regulatory 
subunit of phosphatidyl-inositide-3 kinase to tumor necro-
sis factor-receptor-1 (TNF-R1). (A) Representative Western 
blots of p85 regulatory subunit of phosphatidyl-inositide-3 
kinase (row 1) and TNF-R1 (row 2) after immunoprecipitation 
of TNF-R1 from human lung microvascular endothelial cells 
treated with TNFα (20 ng/ml) in the absence or presence of 
ropivacaine (1 nM) for 10 min. Normal mouse immunoglobulin 
G (IgG) served as negative control for immunoprecipitation 
(lane 1). (B) Quantitative analysis of densitometry of Western 
blots from coimmunoprecipitation showing the ratio of p85 
over TNF-R1 in human lung microvascular endothelial cells 
treated with TNFα (20 ng/ml) for 10 min in the absence (black 
bar) or presence (striped gray bar) of ropivacaine (1 nM) com-
pared with untreated cells (white bar, set as 1.0). Data shown 
are mean ± SD (n = 6 per group). #P < 0.05 versus untreated 
cells, *P < 0.05 compared with TNFα alone. Fig. 6. Ropivacaine inhibits Src-dependent phosphorylation 
of intercellular adhesion molecule-1 (ICAM-1) and attenu-
ates neutrophil adhesion to endothelial cells. (A) Representa-
tive Western blot of ICAM-1 phosphorylated at tyrosine 512 
(pY512 ICAM-1, row 1), total ICAM-1 (row 2), and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) or β-actin (row 3) 
after treatment with tumor necrosis factor α (TNFα, 20 ng/ml) 
in the absence or presence of ropivacaine (1 nM, 1 μM) for 
20 min. (B) Quantitative analysis of densitometry from Western 
blots showing the ratio of pY512 ICAM-1 over total ICAM-1 in 
human lung microvascular endothelial cells treated with TNFα 
(20 ng/ml) in the absence (black bar) or presence (striped gray 
bars) compared with untreated cells (white bar, set as 1.0). 
Data shown are mean ± SD (n = 6 per group); #P < 0.05 ver-
sus untreated cells, *P < 0.05 compared with TNF-α alone. 
(C) (i) Representative Western blot of ICAM-1 (row 1) and β-actin 
(row 2) after treatment with bacterial lipopolysaccharide (LPS, 
4 μg/ml) for 4 h. (ii) Quantification of adhesion of fluorescently 
labeled human neutrophils to human lung microvascular endo-
thelial cells (pretreated with LPS [4 μg/ml] for 4 h) followed by 
stimulation with TNFα (20 ng/ml) in the absence or presence of 
ropivacaine (1 nM, 1 μM, 100 μM). Data shown (relative fluores-
cence units [RFU]) are mean ± SD (n = 8 per group); #P < 0.05 
versus untreated cells, *P < 0.05 compared with TNFα alone.
Downloaded From: http://anesthesiology.pubs.asahq.org/pdfaccess.ashx?url=/data/Journals/JASA/930981/ on 01/30/2015
Anesthesiology 2014; 120:1414-28 1423 Piegeler et al.
PERIOPERATIVE MEDICINE
Ropivacaine Inhibits Src-dependent Phosphorylation 
of Caveolin-1 and Disruption of Endothelial Monolayer 
Integrity
Src-dependent phosphorylation of caveolin-1 tyrosine 14 
(pY14 Cav-1) leads to endothelial barrier dysfunction.8 
Incubation of HLMVEC with ropivacaine at different 
concentrations for 20 min did not alter basal pY14 Cav-1 
(P = 0.311, data not shown). As shown in figure 7, A and B, 
TNFα induced a 36 ± 46% increase in caveolin-1 phosphor-
ylation, which was not considered to be statistically signifi-
cant (P = 1). However, in the presence of 1 nM ropivacaine, 
we did not observe a significant increase in TNFα-induced 
caveolin-1 phosphorylation compared with untreated cells 
(P = 0.4522) but saw a reduction of 35 ± 18% compared 
with TNFα alone (P = 0.012; fig. 7, A and B).
Endothelial barrier disruption induced by TNFα (i.e., 
decrease in monolayer integrity which is thought to repre-
sent an increase in paracellular permeability)25 was evalu-
ated by measuring TER of HLMVEC monolayers grown on 
 gold-film electrodes. HLMVECs were treated with TNFα 
(20 ng/ml), ropivacaine (1 μM), TNFα + ropivacaine, 
TNFα + NOS-inhibitor L-NIO (20 μM, pretreatment for 
1 h before addition of TNFα), TNFα + Src-inhibitor PP2 
(10 μM, pretreatment for 30 min before addition of TNFα), 
or were left untreated (control). TER was measured over time 
and normalized to baseline values as shown in figure 7C. 
TNFα decreased monolayer resistance at 6 h (fig. 7D) by 
57 ± 20% (P < 0.001) compared with untreated monolay-
ers, respectively. Coincubation of cells with TNFα and 1 
μM of ropivacaine significantly blocked the decrease in TER 
induced by TNFα alone by 42 ± 19.3% at 6 h (P = 0.006). 
As positive controls, pretreatment of monolayers with NOS 
and Src inhibitors L-NIO and PP2, respectively, was shown 
to also significantly attenuate the TNFα-induced decrease in 
TER at 6 h (P < 0.001 for L-NIO, P = 0.049 for PP2).
Discussion
Inflammatory vascular hyperpermeability is mediated in part 
by Src-dependent signaling,8,14–17,29,30 and thus Src may be a 
therapeutic target in the pathogenesis of inflammatory dis-
eases such as acute lung injury, ARDS, cancer, and diabe-
tes mellitus.1,3,4,7,18,22 In the current study, we characterized 
the molecular mechanism by which the amide-linked local 
anesthetics ropivacaine and lidocaine block inflammatory 
Src signaling induced by TNFα. In functional studies in 
which human endothelial cells were used, we observed that 
TNFα-induced neutrophil binding and loss of endothelial 
monolayer integrity could be abolished in cells simultane-
ously treated with ropivacaine. The concentrations of ropi-
vacaine and lidocaine that were effective (1 nM to 1 μM) are 
clinically relevant and consistent with a recent study which 
reported a well-tolerated, mean (total) maximal plasma con-
centration of 1.82 mg/l (5.5 μM) during continuous epi-
dural infusions of 0.2% ropivacaine at a rate of 10 mg/h for 
48 h after major abdominal or urologic surgery.31
Previous studies have also shown a protective effect of 
local anesthetics on endothelial cell viability and func-
tion.32,33 However, these studies primarily focused on the 
inhibition of effects of prolonged (>24 h) cytokine expo-
sure and used concentrations of local anesthetics up to 
100,000 times higher than that used in the current study32,33 
although still much lower than concentrations required to 
achieve effective blockade of voltage-gated sodium channels 
(IC50 of 50 to 100 μM).
34,35 Interestingly, in an earlier study, 
we observed that inhibition of TNFα-induced Src activation 
by local anesthetics occurs independently of sodium channel 
blockade.22 Due to their lipophilic nature, local anesthet-
ics distribute into cell membranes, affect their dynamics,36 
and interfere with the function of membrane-associated 
proteins like the G-protein–coupled m1 muscarinic acetyl-
choline receptor,37 also at a much lower concentration (the 
IC50 for lidocaine was 18 nM) than that which is necessary 
for sodium channel inhibition. Uniquely, the current report 
focused on the effect of amide-linked local anesthetics on 
rapidly appearing TNFα-induced signaling events known 
to be activated during the initial phase of vascular inflam-
mation.16 We demonstrated specific inhibition of agonist 
(TNFα)-induced activation of signaling enzymes, but saw 
no effect on basal signaling, which might also be a possible 
explanation for the low IC50 values observed.
The mechanism(s) that account for the now 
 well-established anti-inflammatory as well as anti-metastatic 
actions of local anesthetics requires further investigation.18,22 
There are structural similarities between ropivacaine (and 
lidocaine) and commercially available Src kinase inhibi-
tors such as the combined Bcr-Abl/Src inhibitor Dasat-
inib® (Bristol-Myers Squibb Company, Princeton, NJ).38,39  
Both types of drugs share an amide-linked phenyl group 
with substitution at positions 2 and 6, whereas the phe-
nyl ring in local anesthetics shows two methyl groups and 
Dasatinib® one methyl and one chloride.39,40 Interest-
ingly, this particular part of Dasatinib® is important in the 
mechanism of inhibition, as it binds (and therefore blocks) 
to the hydrophobic pouch of the adenosine triphosphate 
binding pocket within the kinase.38 Our investigations, 
however, indicate that ropivacaine does not act as a com-
petitive inhibitor of adenosine triphosphate binding in the 
Src kinase active site, that is, the common target of most 
kinase inhibitors.38 To address other possible targets of local 
anesthetics such as ropivacaine and lidocaine, we interro-
gated potential signaling intermediates known to play a role 
in TNFα-induced Src activation.
Src activity in cultured cells and tissues is often assessed 
by measuring the phosphorylation status of active-site Src 
tyrosine 419 and inhibitory tyrosine 529 residues.8 eNOS 
activation and nitric oxide generation play an important 
role in Src activation10 and were significantly inhibited by 
ropivacaine and lidocaine in our experiments. A reduction 
of (lipopolysaccharide-induced) nitric oxide production by 
lidocaine in bovine aortic endothelial cells has previously 
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been reported, and the authors provided some evidence that 
the observed inhibition might (in part) have been due to a 
suppression of L-arginine uptake by the cells.41 Nitric oxide–
dependent S-nitrosation of Src at cysteine 498 has also been 
reported not only to increase Src activity but also to lead to 
the disruption of cell–cell junctions.9
Akt protein kinase is known to activate eNOS via direct 
phosphorylation of serine 1177.42,43 Our studies demon-
strate no effect of ropivacaine on Src activation induced 
by Ca2+ ionophore, a non–Akt-dependent activator of 
eNOS, but inhibited TNFα-induced Akt activation sug-
gesting the site of ropivacaine action may be upstream of 
Akt, for example via inhibition of PI3K. PI3Ks are divided 
into three different classes, class I, II, and III, and class I 
PI3K consists of two subgroups, IA and IB.44 The class I 
PI3K isoforms function as heterodimers of the regulatory 
p85 subunit (of which there are two isoforms, p85α and 
p85β) and the catalytic p110 subunit (α, β, δ isoforms in 
class IA; γ isoform in class IB).45 PI3K phosphorylates the 
3’-OH residue of the inositol ring of phosphatidylinosi-
tol-(4,5) phosphate (PIP2) to generate PIP3, a lipid sec-
ond messenger that has been shown to activate Akt and 
phosphoinositide-dependent kinase-1.44,46 By using the 
principle of PIP3 generation by PI3K in an in vitro kinase 
Fig. 7. Ropivacaine inhibits tumor necrosis factor-α (TNFα)–induced Src-dependent phosphorylation of caveolin-1 and attenu-
ates endothelial barrier disruption. (A) Representative Western blots of caveolin-1 phosphorylated at tyrosine 14 (pY14 Cav-1, 
row 1), total Cav-1 (row 2), and β-actin (row 3) after treatment with TNFα (20 ng/ml) in the absence or presence of ropivacaine 
(1 nM, 1 μM) for 20 min. (B) Quantitative analysis of densitometry of Western blots showing the ratio of pY14 Cav-1 over total 
Cav-1 in human lung microvascular endothelial cells treated with TNFα (20 ng/ml) in the absence (black bar) or presence (striped 
gray bars) of ropivacaine compared with untreated cells (white bar, set as 1.0). Data shown are mean ± SD (n = 8); *P < 0.05 com-
pared with TNFα alone. (C) Transendothelial electrical resistance of endothelial monolayers over time (normalized to baseline 
values). After 30-min equilibration, cells were incubated (arrow indicates beginning of treatment) with either TNFα (20 ng/ml, red), 
ropivacaine (1 μM, purple), TNFα + ropivacaine (blue), TNFα + nitric oxide synthase Inhibitor N5-(1-iminoethyl)-L-ornithine dihy-
drochloride (L-NIO) (yellow, pretreatment for 1 h before addition of TNFα), TNFα + Src-inhibitor PP2 (gray, pretreatment for 30 min 
before addition of TNFα), or vehicle (control, green). Data shown are mean ± SD of normalized resistance (n = 7 per group). 
(D) Quantification of decrease in normalized resistance at 6 h. Data shown are mean ± SD; untreated cells (white bars), ropiva-
caine at 1 μM (light gray bars), TNFα alone (black bar), TNFα + ropivacaine 1 μM (dark gray bars), and TNFα + L-NIO (striped 
bars), TNFα + PP2 (checkered bars); n = 7 per group; #P < 0.05 versus untreated cells, *P < 0.05 compared with TNFα alone.
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assay, we showed that ropivacaine does not directly inhibit 
PI3K activity.
An alternative pathway leading to Src activation on stim-
ulation with TNFα might be the generation of superoxide 
anions (O2
−), for example by nicotinamide adenine dinucleo-
tide phosphate-oxidase (NOX) via a pathway involving the 
activation of protein kinase C-ζ downstream of PI3K (fig. 8, 
gray arrows) as the stimulation of endothelial cells with TNFα 
was shown to induce a PI3K-dependent rapid increase in pro-
tein kinase C-ζ activation.16,47 Protein kinase C-ζ–mediated 
phosphorylation of p47phox is thought to initiate the assembly 
and activation of the NOX complex.48 The oxidants pro-
duced have been shown to activate Src as well.49,50
The results of the current study, however, indicate 
that ropivacaine blocks TNFα-induced Src activation 
upstream of PI3K. On the binding of TNFα to its pri-
mary receptor in endothelial cells, TNF-R1, p85 is 
recruited to the receptor which leads to the assembly of 
the p85 and p110 heterodimer and thereby to activation 
of PI3K13 (fig. 8). Interestingly, we observed a diminished 
recruitment of p85 to TNF-R1 by ropivacaine in co-
immunoprecipitation experiments of TNF-R1 and p85 in 
HLMVEC suggesting that ropivacaine may block TNFα 
signaling by disrupting TNF-R1–mediated PI3K activa-
tion, Akt phosphorylation, and eNOS-dependent nitric 
oxide production.
The initiation of transmembrane signaling via TNF-R1 
includes oligomerization of ligand–receptor complexes,51 
and there is some evidence that certain anesthetics (as shown 
for the less common local anesthetic phenylethanol) are able 
to inhibit oligomerization of transmembrane proteins.52 In 
addition, it has been shown that amide-linked local anes-
thetics alter membrane fluidity as well as conformation of 
membrane proteins.53,54 Thus, on the basis of the results 
of the current study, we speculate that inhibition of p85 
recruitment might be due to alteration in the conformation 
of TNF-R1 or attenuation of its ability to oligomerize to 
initiate signaling across the membrane.51
In endothelial cells, we previously demonstrated that 
TNFα-induced Src activation leads to ICAM-1 tyrosine 
512 phosphorylation which, by promoting actin-mediated 
ICAM-1 clustering, increases the avidity of neutrophil 
binding during the rapid, initial phase of inflammation.16 
Subsequently, this rapid increase in endothelial cell adhesive-
ness leads to accelerated recruitment of circulating neutro-
phils and development of inflammation.16 Ropivacaine was 
shown to inhibit TNFα-induced Src-dependent ICAM-1 
phosphorylation as well as neutrophil adhesion to monolay-
ers of HLMVECs, thus supporting the hypothesis that ropi-
vacaine has beneficial anti-inflammatory effects by blunting 
TNFα-mediated endothelial cell activation.
Src-dependent caveolin-1 tyrosine 14 phosphorylation 
also contributes to the development of inflammatory vas-
cular hyperpermeability.8,29,30 In response to thrombin or 
reactive oxygen species (H2O2), that is, agents that induce 
the disruption of endothelial monolayer integrity,29,55 phos-
phorylated caveolin-1 promotes disruption of vascular endo-
thelial–cadherin/catenin interactions,29 perhaps by binding 
to catenins directly.56 Disruption of cadherin/catenin inter-
actions thought to be essential in the regulation of adherens 
junction stability,57,58 leads to disassembly of these cell–cell 
junctions and thereby an increase in transcellular endothe-
lial permeability.56 Alternatively, active Src may have directly 
modified vascular endothelial–cadherin in response to TNFα 
as it was shown that Src phosphorylation of vascular endo-
thelial–cadherin tyrosine residues 658 and 685 in venous 
endothelial cells59 promotes vascular endothelial–cadherin 
internalization, ubiquitination, and degradation, ultimately 
resulting in endothelial barrier disruption and increased vas-
cular permeability.58,59
Local anesthetic-mediated inhibition of Src-dependent 
ICAM-1 and caveolin-1 phosphorylation may be a poten-
tial mechanism for blocking endothelial barrier disruption 
Fig. 8. Summary of proposed mechanism of inhibition of inflam-
matory Src signaling by local anesthetics. Local anesthetics (LA) 
inhibit recruitment of p85 regulatory subunit (p85) of phospha-
tidyl-inositide-3 kinase (PI3K) to tumor necrosis factor-α (TNFα) 
receptor 1 (TNF-R1), thus preventing PI3K activation and sub-
sequent signaling involving phosphorylation/activation of Akt, 
endothelial nitric oxide synthase (eNOS), nitric oxide (NO) gen-
eration, and Src activation. Inhibition of Src-dependent intercel-
lular adhesion molecule-1 (ICAM-1) phosphorylation blocks the 
increase in neutrophil binding, and the inhibition of direct and 
indirect (via the phosphorylation of caveolin-1) Src-dependent 
destabilization of adherens junctions attenuates endothelial 
barrier disruption and hyperpermeability. An alternative path-
way (gray arrows) leading to Src activation might involve protein 
kinase C (PKC), nicotinamide adenine dinucleotide phosphate-
oxidase (NOX), and the generation of superoxide anions (O2
−).
Downloaded From: http://anesthesiology.pubs.asahq.org/pdfaccess.ashx?url=/data/Journals/JASA/930981/ on 01/30/2015
Anesthesiology 2014; 120:1414-28 1426 Piegeler et al.
Anti-inflammatory Effect of Local Anesthetics
during acute inflammation. In addition, inhibition of TNFα-
induced PI3K activation by ropivacaine upstream of Src 
might also be clinically relevant. In a recent study, it was 
shown that the phosphatidylinositol (3,4,5)-trisphosphate-
dependent Rac exchanger 1 (P-Rex1) mediates TNFα-
induced endothelial barrier disruption.25 As ropivacaine 
inhibits  TNF-R1-mediated PI3K activation, it should also 
decrease PIP3 generation and attenuate P-Rex1 activation60 
and signaling.25
In conclusion, this study illustrates a novel 
 anti-inflammatory mechanism of action of the local anesthet-
ics ropivacaine and lidocaine. We demonstrate that in addition 
to the well-described action of Na+ channel blockade, local 
anesthetics also blocked TNFα-induced  TNF-R1-dependent 
PI3K, Akt, and eNOS activation resulting in the inhibition 
of nitric oxide–driven Src signaling. We also showed that the 
inhibition of Src activation by the local anesthetics blocked 
TNFα-induced neutrophil adhesion and endothelial bar-
rier disruption (inflammatory hyperpermeability). Thus, 
local anesthetics may have significant therapeutic benefit by 
attenuating vascular inflammation which we predict would 
minimize microvascular endothelial injury and inflammatory 
hyperpermeability associated with the pathogenesis of acute 
lung injury, ARDS, diabetes mellitus, and cancer.
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